Navigation Links
Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
Date:9/25/2007

medications, and must have at least 60 percent stenosis or blockage in a renal artery as measured by visual X-ray angiography.

"We are pleased to begin enrollment in a study to examine the safety and effectiveness of stenting for patients with renal artery disease and uncontrolled high blood pressure," said Chuck Foltz, vice president, Abbott Vascular. "Abbott Vascular has a strong history of innovation and leadership in vascular care, and with the HERCULES trial we can continue to expand our understanding of vascular disease and how to deliver the best treatments for patients."

About the HERCULES Trial

Abbott is conducting the HERCULES trial to seek U.S. Food and Drug Administration approval for use of the RX Herculink Elite Renal Stent System in the treatment of renal artery stenosis.

The HERCULES trial will enroll up to 202 patients at approximately 50 sites across the United States. The primary endpoint of the study is binary restenosis at nine months, a measure of vessel renarrowing. Secondary endpoints in the trial will measure changes in blood pressure and the use of hypertensive medication at nine months. Additional analyses in patient follow-up visits out to 36 months will measure major adverse events in patients such as death, surgical removal of the kidney, or embolic events resulting in kidney damage, as well as target lesion revascularization (TLR), a measure of the need to retreat a diseased vessel that has renarrowed.

About the Investigational RX Herculink Elite Renal Stent System

The RX Herculink Elite Renal Stent System is an .014-inch rapid-exchange (single-operator) renal stent system made of cobalt chromium, a material that is stronger and easier to see under X-ray than stainless steel.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving pa
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
11. Malvern initiates European user group meetings for chemical imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® extracorporeal cytokine adsorber to purify ... of Dr. Joerg Scheier , M.D. as ... is a specialist in intensive care medicine and ... experience in treating critically-ill patients and in the ...
(Date:4/27/2015)... Pa. , April 27, 2015  Novira Therapeutics, ... therapies for curative treatment of chronic hepatitis B virus ... data for its lead HBV core inhibitor candidate, NVR ... Association for the Study of the Liver (EASL) in ... antiviral activity of NVR 3-778 from studies performed in ...
(Date:4/27/2015)... -- BRH Medical, Ltd., today announced that ... Application (510k) with the US Food and Drug Administration ... expects feedback from the FDA during the next quarter ... FDA pre-market clearance. Additional pre-market regulatory filings are anticipated ... for BRH Medical, commented, "We are thrilled to have ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 2CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 3CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 4CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 5Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2
... ® Products is pleased to announce ... was developed to support the recent introduction of LimbO Waterproof Protectors ... Products in the United Kingdom, LimbO Waterproof Protectors enable children and ... cast or a bandage. The waterproof cover is simply slipped on ...
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
Cached Medicine Technology:LimbO® Products Launches New U.S. Website 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
(Date:4/27/2015)... A new type of festival is emerging in ... Tap at the Science Museum of Virginia not only fills ... hops for a bold, new flavor. , The 21+ festival ... the science behind these frothy beverages. Guests uncover the brewing ... the ingredients that go into beer with Original Gravity and ...
(Date:4/27/2015)... April 27, 2015 A variety of events ... people trapped in substance abuse. Programming for Jericho for boys ... girls, is launching this summer. , The first event is ... to serve adolescents. The Youth Town Jim Jackson Golf Classic ... Monday, May 4, with tee times at 8 a.m. and ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Moreno Ranches, ... http://www.morenoranches.com/ , is proud to announce their "This is ... interested in Brahman cattle breeding and education was a ... Florida, on April 18, 2015. It brought together ... future interest in cattle breeding in general, and Brahman ...
(Date:4/27/2015)... April 27, 2015 Jesse L. Goodman, ... United States Pharmacopeial Convention (USP) at the recently concluded ... of Medicine at Georgetown University and the Director of ... (COMPASS). , As USP President, a volunteer position, Dr. ... He will be a voting member, ex officio, of ...
(Date:4/27/2015)... "Understanding Mental Disorders: Your Guide to the ... Psychiatric Publishing, a division of the American Psychiatric Association. ... National Press Club in Washington, D.C.. The launch event ... President Paul Summergrad, MD. Guest speakers will include Former ... the book; Paul Gionfriddo, President and CEO of Mental ...
Breaking Medicine News(10 mins):Health News:Science on Tap at the Science Museum of Virginia 2Health News:Golf, Sermon on the Mount and More to Support Youth Town’s Jericho and Eden Programs 2Health News:Leading Ranch for Brahman Cattle for Sale, Moreno Ranches, Announces Conclusion of 'This is It' Event for Brahman Juniors. 2Health News:Dr. Jesse Goodman Elected President of the USP Convention 2Health News:American Psychiatric Association, Patrick Kennedy To Debut New Consumer Guidebook “Understanding Mental Disorders” 2
... of these infant medicines, not product safety, is ... the voluntary withdrawal,- This withdrawal does not affect cough and cold medicines for children ... ... for infants and,children will occur at the October 18 and 19 FDA advisory committee ...
... Oct. 11 Businesses can no longer afford ... spend more than,75 billion dollars on obesity-attributable health ... are lost to obesity-related illness each,year(2). Other costs ... and high turnover rates. Today, business leaders, ...
... * concentrated Tylenol(R) Infants, Drops Plus Cold and ... * PediaCare(R) Infant Drops ... division of McNeil-PPC, Inc., announced today that the,company is voluntarily withdrawing ... directed, these medicines are generally,recognized as safe and effective. While most ...
... and Multimedia Healthcare Communication, PARIS, October 11 ... today two key acquisitions designed to reinforce its ... acquisitions,aim at strengthening Publicis Groupe,s leadership in both ... (Salerno), a highly innovative agency, specialized in,digital communications ...
... Has,a Story," a grassroots and integrated media project celebrating babies ... to survive and thrive --,has been launched by the March ... over the country tell,a special story about the baby they ... March of Dimes. "Families can also express their,hopes and dreams ...
... SACRAMENTO, Calif., Oct. 10 The governor ... (CSU) retirees to,participate in a self-funded comprehensive vision ... the Legislature and governor have recognized,the need to ... said,Barbara LaPlante, President of CSEA Retirees, Inc. "When ...
Cached Medicine News:Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 2Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 2Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 4Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 2Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 4Health News:'Every Baby Has a Story' Campaign Tours the Nation for March of Dimes 2Health News:Governor Signs Bill Providing Vision Care Program for State University Retirees 2
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Our 'flex' removes the apron weight from the shoulders while providing back support. Unlike other elastic backs, ours does not wrinkle up, making cleaning easier....
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
This battery-powered, single-use pulsed stimulator delivers approximately 0.7mA at 80 pulses per second and uses a subdermal needle as the grounding (anode) electrode. A "current flow" confirmation l...
Medicine Products: